Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective.

Gregg, Emily, Graziadio, Sara, Green, William, Afonso, Daniela, Garrett, Monica, Watts, Karina, Watkins, Deborah, Carrol, Enitan D ORCID: 0000-0001-8357-7726, Cooke, Jonathan and Felton, Tim (2025) Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective. JAC-antimicrobial resistance, 7 (1). dlaf016-dlaf016. ISSN 2632-1823, 2632-1823

PDF Host-response testing with MeMed BV in community-acquired pneumonia an economic evaluation from the UK NHS perspective.pdf - Open Access published version Available under License Creative Commons Attribution. Download (400kB) | Preview

Abstract

<h4>Background</h4>Community-acquired pneumonia (CAP) remains a leading cause of hospital admissions and mortality. A novel host-response test, MeMed BV (MMBV), has been developed for discriminating between bacterial and viral infection that could improve the clinical management of CAP.<h4>Objectives</h4>To evaluate the cost-effectiveness of using MMBV to guide antibiotic decisions in the clinical management of CAP in the UK.<h4>Methods</h4>An economic model was developed to understand the incremental cost per person associated with the implementation of MMBV from the UK NHS perspective. A qualitative care pathway analysis was performed to inform the standard of care (SOC) and SOC plus MMBV (SOC + MMBV) clinical pathways captured in the model.<h4>Results</h4>In the base case analysis, the SOC + MMBV strategy for a hypothetical cohort of 1000 patients (adults and children modelled independently) presenting to the emergency department with suspected CAP was estimated to provide total cost savings of £134 018 and £105 750 for adults and children, respectively. Cost savings were associated with reductions in total antibiotic treatment, the number of patients receiving additional diagnostic tests, and hospital admissions. Deterministic sensitivity analysis revealed that the specificity of SOC + MMBV and sensitivity of the SOC were primary drivers of the cost model for adults, whereas the specificity of SOC and SOC + MMBV were primary drivers for paediatrics.<h4>Conclusions</h4>Overall, the model predicts that the introduction of SOC + MMBV has the potential to be cost-saving and promote antimicrobial stewardship for both adult and paediatric CAP patients.

Item Type:	Article
Uncontrolled Keywords:	32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Pneumonia, Pneumonia & Influenza, Comparative Effectiveness Research, Cost Effectiveness Research, Lung, Infectious Diseases, Clinical Research, Health Services, 4.2 Evaluation of markers and technologies, Infection, 3 Good Health and Well Being
Divisions:	Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Inst. Infection, Vet & Ecological Sciences
Depositing User:	Symplectic Admin
Date Deposited:	03 Mar 2025 09:08
Last Modified:	28 Feb 2026 20:48
DOI:	10.1093/jacamr/dlaf016
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3190615
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.